Novartis Valuation Hinges on Key Drug Trial Results

Novartis is poised for pivotal moments in the latter half of 2026, with investors closely monitoring three crucial drug trial readouts. The experimental treatments—pelacarsen for cardiovascular disease, remibrutinib for multiple sclerosis, and del-desiran for a genetic disorder—are seen as cornerstones for the company's growth into the next decade.

These upcoming results are particularly significant as Novartis navigates its largest patent expiry period. The potential peak annual sales for these three drugs are estimated to exceed $10 billion, a figure that would offset expected patent losses for top-selling medications like Cosentyx and Kisqali.

Analysts suggest that much of Novartis' current market valuation, which stands at approximately 16 times forward earnings, already factors in the anticipated success of these trials. A failure in even one key trial could place this premium valuation under considerable pressure.

Management's communication regarding the progress and significance of these trials will be paramount. Investors are keen to understand the likelihood of "clinically meaningful" benefits, a metric crucial for regulatory approval and market adoption, especially for pelacarsen, which targets a condition with no current market alternatives.